5-Amino-1MQ

The 5-Amino-1MQ evidence base cited here is 8 sources — 8 preclinical. Critically, that evidence is almost entirely preclinical (animal and in-vitro) — no human clinical trials are cited, so efficacy and safety in people remain unproven. Regulatory status: Not FDA-approved.

• 5-Amino-1MQ is a small molecule (not a peptide) that inhibits the enzyme NNMT (nicotinamide N-methyltransferase), which in turn helps preserve cellular NAD+ and supports mitochondrial and metabolic function.
• The entire evidence base is preclinical — there are no published human clinical trials. Every dose discussed below is extrapolated from animal studies.
• It is taken orally; reported animal data put oral bioavailability around 38% with an oral half-life near 7 hours.

5-Amino-1MQ (5-amino-1-methylquinolinium) is a research compound studied for metabolism and longevity. Mechanistically it is an inhibitor of NNMT, an enzyme that consumes the NAD+ precursor pathway; by blunting NNMT it is proposed to raise or preserve cellular NAD+ and, through that, support mitochondrial function, energy metabolism, and possibly fat metabolism.

One thing to be clear about up front: despite appearing alongside peptides, 5-Amino-1MQ is a small molecule, not a peptide. And its evidence is entirely preclinical — animal and cell studies only. There are no human clinical trials, no FDA approval, and no validated human dosing. Everything here is research context, not medical guidance.

It is a small-molecule, orally available inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT methylates nicotinamide (a precursor in the NAD+ salvage pathway); over-activity of NNMT is associated with depleted NAD+ and metabolic dysfunction in fat and muscle tissue. Inhibiting the enzyme is the lever 5-Amino-1MQ is designed to pull.

Because it is a small molecule rather than a peptide, it survives oral administration far better than most compounds discussed on this site — which is why it is studied as a once-daily oral capsule rather than an injectable.

• Oral bioavailability ~38% (rat data)
• Time to peak: roughly 48 minutes
• Half-life: ~7 hours oral (≈3.8 hours IV in rats); largely cleared within ~1.7 days

All pharmacokinetic figures are from animal studies. Human PK has not been characterized.

There is no validated human dose. The ranges below are what appear in research and anecdotal use, extrapolated from animal studies and included for research context only — not as a protocol.

• Reported research-use range: ~25–100 mg once daily, taken orally with food
• Conservative starting points (~25–50 mg) are used to assess tolerance
• Taken earlier in the day to avoid any effect on sleep
• Some protocols cycle (e.g. several weeks on, then off) — there is no evidence base establishing an optimal schedule

Because no human trial has defined a safe or effective dose, these figures carry more uncertainty than the dosing on our FDA-approved-drug pages.

• Aged-mouse muscle study (2024): ~10 mg/kg/day for 8 weeks improved grip strength substantially (reported ~40%, and more when combined with exercise), with no adverse effects observed.
• Mouse obesity study (Neelakantan et al., 2018): ~60 mg/kg/day over 11 days produced ~5% weight loss and reduced adipocyte size; the authors back-calculated a human-equivalent of roughly 5 mg/kg/day by allometric scaling.
• Rat pharmacokinetic study (2021): established the ~38% oral bioavailability and oral/IV half-lives.

These are animal results. They motivate human research but do not establish that 5-Amino-1MQ works — or is safe — in people.

No human safety data exists. Animal studies reported minimal adverse effects at the doses tested, but that does not establish human safety. General research-handling cautions: start at the low end to assess tolerance, take with food, and discontinue if any adverse effect appears. Not for use in pregnancy or breastfeeding.

• Pre-made capsules are the most practical form; powder requires an accurate milligram scale for dosing.
• Store cool and dry, away from light and moisture.
• Quality indicators: uniform white-to-off-white capsules/powder, sealed packaging, and a third-party COA showing >98% purity with heavy-metals testing.
• Warning signs: moisture damage, clumping or stickiness, discoloration, or a strong chemical odor (possible contamination or degradation).

5-Amino-1MQ is not approved by the FDA or any regulatory agency for any indication. It is sold as a research chemical for laboratory use only and is not intended for human consumption.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.